+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clinical Bioenergetics

  • ID: 5029607
  • Book
  • November 2020
  • 600 Pages
  • Elsevier Science and Technology
1 of 3

Clinical Bioenergetics: From Pathophysiology to Clinical Translation provides recent developments surrounding the etiology and pathophysiology of inherited and acquired energy-delated disorders. Across 40 chapters, world leaders in bioenergetics and mitochondrial medicine discuss novel methodologies designed to identify deficiencies in cellular bioenergetics, as well as the safety and efficacy of emerging management strategies to address poor cellular bioenergetics. Topics discussed include the omics landscape of impaired mitochondrial bioenergetics, hormones, tissue bioenergetics and metabolism in humans. Disease-specific case studies, modes of analysis in clinical bioenergetics, and therapeutic opportunities for impaired bioenergetics, addressing both known treatment pathways and future directions for research, are discussed in-depth.

Diseases and Disorders examined include brain injury, chronic fatigue syndrome, psychiatric disorders, pulmonary fibrosis, neurodegenerative disorders, heart failure, chronic kidney disease, obesity, and insulin resistance, among others.

  • Provides a thorough discussion of foundational aspects of bioenergetics and disease, modes of analysis, and treatments for impaired bioenergetics
  • Discusses the role of bioenergetics and treatment pathways in brain injury, chronic fatigue syndrome, psychiatric disorders, pulmonary fibrosis, neurodegenerative disorders, heart failure, chronic kidney disease, obesity, and insulin resistance, among other diseases and disorders
  • Features chapter contributions from international leaders in translational bioenergetics research and clinical practice
Note: Product cover images may vary from those shown
2 of 3

Part 1: Foundational Aspects of Bioenergetics and Disease 1. Tissue specificity of energy metabolism in mitochondria 2. Sex hormones, tissue bioenergetics and metabolism in humans 3. Impaired mitochondrial bioenergetics and signalling pathways: an overview

Part 2: Disease-Specific Case Studies 4. Abnormal mitochondrial metabolism in obesity and insulin resistance 5. Impaired mitochondrial energy metabolism: Etiologies and implications in neurodegenerative disease 6. Mitochondrial dysfunction and kidney disease 7. Role of mitochondria in non-alcoholic liver disease as a chronic disorder 8. Decreased bioenergetics in traumatic brain injury 9. Impaired mitochondrial bioenergetics in psychiatric disorders 10. Mitochondrial dysfunction and impaired bioenergetics of pulmonary fibrosis 11. Mitochondrial dysfunction and impaired bioenergetics in skin diseases

Part 3: Modes of Analysis in Clinical Bioenergetics 12. Monitoring mitochondrial oxygenation in clinical environment 13. Assessing metabolic flexibility and mitochondrial bioenergetics 14. Assessing the real-time metabolism and bioenergetics of single cells using fluorescence biosensors 15. Blood-based bioenergetic profiling in clinical environment 16. Bioenergetic profiling in the skin 17. Evaluating tissue bioenergetics via magnetic resonance spectroscopy 18. Targeting respiratory complex I
molecular mechanism and drug design

Part 4: Theraputic Opportunities for Impaired Bioenergetics 19. Models for target effects of drugs on mitochondrial bioenergetics 20. Gene therapy for impaired mitochondrial bioenergetics 21. Mitochondria replacement as an innovative treatment to tackle impaired bioenergetics in clinical medicine 22. Mitochondrial drug delivery systems: therapeutic applications for clinical bioenergetics 23. Dietary interventions for patients with obesity and impaired bioenergetics 24. Novel nutraceuticals to tackle brain and muscle bioenergetics 25. Therapeutic potential of cardiolipin-protective compound to restore mitochondrial bioenergetics 26. NEET proteins as novel drug targets for mitochondrial dysfunction 27. Translation of bioenergetics therapies: challenges from bench to bedside 28. New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders 29. Targeting impaired bioenergetics in heart failure 30. Pharmacological targeting of mitochondria in cancer 31. Modulation of the mitochondrial function with natural bioactive compounds to treat obesity and insulin resistance 32. Antioxidants and natural derived products in the modulation of Mt bioenergetic dysfunction in chronic kidney disease 33. Transcranial and systemic photobiomodulation for the enhancement of mitochondrial metabolism in depression 34. Impairments in oxidative glucose metabolism in epilepsy and advanced metabolic treatments: an overview

Note: Product cover images may vary from those shown
3 of 3
Ostojic, Sergej M.
Dr. Sergej M. Ostojic is a Full Professor in the Biomedical Sciences Department of the University of Novi Sad, Belgrade, Serbia. His current research is focused on evaluating effectiveness and safety of novel mitochondria-targeted nutraceuticals (including molecular hydrogen, creatine salts and guanidinoacetic acid) tackling impaired bioenergetics in health and disease. To date, he has authored and co-authored over 160 peer-reviewed research and review articles in high-impact journals, such as The Lancet, Trends in Endocrinology and Metabolism, Theranostics, Sports Medicine, Mayo Clinic Proceedings, Clinical Science, Pharmacological Research, International Journal of Cardiology, and the European Journal of Nutrition. He is a member of the American Society for Nutrition, the American Physiological Society, the American College of Sports Medicine, and the Nutrition Society, and has been the recipient of internationally research grants such as the World Anti-Doping Agency and NSCA International Award. Dr. Ostojic holds 4 patents in the US, UK, EU, and Japan.
Note: Product cover images may vary from those shown
Adroll
adroll